fashion -WSS

fashion

author：leisure time 2025-09-27 19:38:25 - browse：733

Apellis Pharmaceuticals said Tuesday that it had identified “internal structural variations” in a type of needle used by doctors to prepare syringes of its eye disease drug Syfovre as a possible cause of severe eye inflammation reported in patients receiving the treatment — but the company stopped short of definitively linking the needle to the cases.

Additionally, Apellis confirmed one additional case of the severe and potentially blinding side effect, known as retinal occlusive vasculitis, or ROV, that occurred in May. But with thousands of more Syfovre eye injections also performed, the overall frequency of ROV remains unchanged and rare, even with the added scrutiny and increased physician monitoring.

Apellis shares rose 30% to $40 in Wednesday’s pre-market trading on the growing belief amongst investors that Syfovre’s safety crisis is abating.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： How to make Best Hospitals ratings actually useful for patients

leisure time

WSS

2024 GOP presidential candidates spar over abortion in debate

How Long Island became the ‘eugenics capital of the world’

Cigna wins case to block Amy Bricker's move to CVS

Neuroscience startup Neumora files for IPO

How to make AI work for medicine

Coercive sterilizations revealed by STAT prompt outrage

explore

fashion

focus

Walensky prepares to leave CDC — and Congress — behind

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Walensky prepares to leave CDC — and Congress — behind

Radiation, mainstay of cancer treatment, begins a fade

Novavax promises a turnaround & Lilly roils the obesity market

Lilly's Alzheimer's drug donanemab backed by FDA advisers

State Dept. review finds Biden bears some blame for Afghanistan failures

Diversity in medical illustrations gets boost from Chidiebere Ibe

ChatGPT in medicine: STAT answers readers' burning questions

Medical device trials still don't enroll enough women, study finds

hotspot

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

California wildfire smoke linked to 52,000 early deaths, study says

Departing Stanford president retracts two papers

Winners, losers from Medicare’s list of drugs subject to price talks

Health care court cases: Humana, Sutter, Novant

Medical device trials still don't enroll enough women, study finds

hotspot

leisure time

hotspot

focus